^
    BIOMARKER:

    KRAS mutation + STK11 mutation + KEAP1 mutation

    i
    Other names: KRAS, KRAS proto-oncogene GTPase, KRAS1, KRAS2, NS, NS3, OES, CFC2, RALD, K-Ras, RASK2, KI-RAS, C-K-RAS, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras 2, C-K-RAS, c-Ki-ras, c-Ki-ras2, Kirsten rat sarcoma viral oncogene homolog, Serine/Threonine-Protein Kinase 11, Liver Kinase B1, Serine/Threonine-Protein Kinase LKB1, Polarization-Related Protein LKB1, STK11, Serine/Threonine Kinase 11, Serine/Threonine-Protein Kinase STK11, Renal Carcinoma Antigen NY-REN-19, KEAP1, Kelch Like ECH Associated Protein 1, Cytosolic Inhibitor Of Nrf2, Kelch-Like Family Member 19, Kelch-Like Protein 19, KLHL19, INrf2, KEAP1 Delta C, KIAA0132, INRF2
    Entrez ID:
    3845; 6794; 9817
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others

    Associations

    Heatmap
    News
    Twitter
    Trials
    KRAS mutation + STK11 mutation + KEAP1 mutation
    NSCLC
    bevacizumab + atezolizumab
    Sensitive: B - Late Trials
    KRAS mutation + STK11 mutation + KEAP1 mutation
    NSCLC
    Immunotherapy
    Resistant: C3 – Early Trials